Common Equity (Annual)

Common Equity: The sum of all common equity items.

Basilea Pharmaceutica AG (BPMUF) had Common Equity of $154.42M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$280.48M
Net Income	$48.57M
Cost of Goods Sold	$47.46M
Gross Profit	$233.02M
Operating Expenses	$218.27M
Operating Income	$62.22M
Non-Operating Income/Expense	$-6.84M
Pre-Tax Income	$55.37M
Normalized Pre-Tax Income	$55.37M
Income after Taxes	$48.57M
Income from Continuous Operations	$48.57M
Consolidated Net Income/Loss	$48.57M
Normalized Income after Taxes	$48.57M
EBIT	$62.22M
EBITDA	$64.41M
Weighted-Average Shares Outstanding (Basic)	12.24M
Weighted-Average Shares Outstanding (Diluted)	12.24M
Earnings per Share (EPS) (Basic)	$3.97
Earnings per Share (EPS) (Diluted)	$3.79
Balance Sheet Financials
Current Assets	$303.84M
Property, Plant, and Equipment	$6.10M
Long-Term Assets	$36.53M
Total Assets	$340.37M
Current Liabilities	$59.40M
Long-Term Debt	$91.06M
Long-Term Liabilities	$126.54M
Total Liabilities	$185.95M
Common Equity	$154.42M
Tangible Shareholders Equity	$153.98M
Shareholders Equity	$154.42M
Common Shares Outstanding	13.32M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$74.94M
Cash Flow from Investing Activities	$-3.45M
Cash Flow from Financial Activities	$-25.86M
Beginning Cash	$150.34M
End Cash	$195.94M
Increase/Decrease in Cash	$45.60M
Stock-Based Compensation	$6.32M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.11
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.37
Debt to Equity Ratio	0.59
Gross Margin	83.08%
Operating Margin	22.18%
EBIT Margin	22.18%
EBITDA Margin	22.96%
Pre-Tax Profit Margin	19.74%
Profit Margin	17.32%
Free Cash Flow	$71.78M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.82
Inventory Turnover	1.82
Receiveable Turnover	3.67
Days Sales in Receivables	99.40
Return on Equity	31.45%
Return on Tangible Equity	31.54%
Return on Assets	14.27%
Return on Investments	19.79%
Book Value Per Share	$11.59
Free Cash Flow per Share	$5.86
Operating Cash Flow per Share	$6.12

Data from Zacks Investment Research, Inc.